Terns Pharmaceuticals, Inc. (TERN) Covered Calls

Terns Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing next-generation specialized therapies for oncology. The company’s lead candidate, TERN-701, is an oral allosteric BCR-ABL inhibitor designed to treat chronic myeloid leukemia (CML) with improved safety and efficacy over current treatments. Terns leverages its expertise in structure-based drug discovery to create small molecules that target well-validated biological pathways in rare diseases.

You can sell covered calls on Terns Pharmaceuticals, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for TERN (prices last updated Fri 4:16 PM ET):

Terns Pharmaceuticals, Inc. (TERN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
37.79 +0.04 37.50 39.00 824K - 3.4
Covered Calls For Terns Pharmaceuticals, Inc. (TERN)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 38 0.10 38.90 -2.3% -104.9%
Mar 20 38 1.65 37.35 1.7% 17.2%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Terns Pharmaceuticals is currently prioritizing its oncology portfolio, specifically the development of TERN-701 for the treatment of chronic myeloid leukemia. TERN-701 is an allosteric inhibitor that targets the BCR-ABL protein, a known driver of CML. By binding to a different site than traditional tyrosine kinase inhibitors (TKIs), it aims to provide a more potent and tolerable alternative for patients who have developed resistance or intolerance to existing therapies. While the company previously maintained a large metabolic pipeline, including candidates for obesity and NASH (such as TERN-601 and TERN-501), these programs have been moved to a partner-only track as the company concentrates its capital on its most promising cancer-fighting assets.

Competitive Landscape

In the oncology space, Terns competes with large pharmaceutical companies and specialized biotechs developing leukemia treatments. Its primary competition includes Novartis AG, which markets the leading BCR-ABL inhibitor Scemblix, and other major players like Bristol-Myers Squibb Company. In the broader metabolic and small-molecule drug discovery arena, Terns is often compared to peers such as Structure Therapeutics Inc. and Crinetics Pharmaceuticals, Inc.. The company differentiates itself through the "allosteric" nature of its lead candidate, which potentially offers a superior safety profile with fewer off-target side effects compared to first- and second-generation ATP-competitive inhibitors.

Strategic Outlook and Innovation

The company’s strategic roadmap is centered on the rapid clinical advancement of the CARDINAL Phase 1/2 trial for TERN-701. Innovation efforts are focused on proving "best-in-class" potential in late-line CML before expanding into earlier lines of treatment. Terns is utilizing optimized dosing and a proprietary formulation designed to enhance drug absorption while maintaining a steady concentration in the bloodstream. Following a significant capital raise in late 2025, the company is well-funded to support its operations through pivotal trials. The long-term strategy includes seeking strategic partners for its legacy metabolic assets to capture value from those programs without further internal R&D expenditure, allowing the management team to remain strictly focused on building a leading oncology franchise.